Measles and rubella elimination country profile: Hungary

Measles elimination status 2015 eliminated 2016 eliminated Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC) Rubella elimination status 2015 eliminated 2016 eliminated Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC) Total population 9 821 318 < 1 year old 91 711 < 5 years old 453 993 Demographic information, 2016 Source: World Population Prospects: The 2015 Revision, New York, United Nations Measles and rubella cases and immunization coverage, 2007–2016 Source: Disease incidence and immunization coverage, WHO, Data and Statistics, Immunization Monitoring and Surveilance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MCV1 = first dose of measles-containing vaccine MCV2= second dose of measles-containing vaccine Definition used for an outbreak At least two measles or rubella cases including cases with epidemiological links Source: Measles and rubella elimination Annual Status Update report, 2016 National plan of action Does the country have a national plan of action? ND Is it updated? ND Source: Rubella Elimination Annual Status Update report, 2016 ND = Data not available Measles and rubella immunization schedule, 2016 Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MMR = measles-mumps-rubella-containing vaccine; MCV1 = first dose measles-containing vacccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine Measles and rubella elimination country profile Hungary Confirmed measles cases by month of onset, 2012-2016 Source: CISID2 2016 0 10 20 30 40 50 60 70 80 90 100 0 1 2 3 4 5 6 7 8 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Measles Rubella Coverage MCV1 Coverage MVC2 Vaccine Schedule MCV1 MMR 15 months MCV2 MMR 11 years Year of introduction MCV2 1989 RCV 1989 Measles vaccination in school Yes 0 1 2 3 4 5 J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D 2012 2013 2014 2015 2016 Suspected measles cases Confirmed measles cases Discarded as non- measles Measles incidence Genotypes detected Laboratory Epi- linked Clincally Total 2012 ND 2 0 0 2 ND 0 D4 2013 6 1 0 0 1 5 0 D4 2014 0 0 0 0 0 0 0 NA 2015 2 0 0 0 0 3 0 NA 2016 1 0 0 0 0 1 0 NA Measles incidence, epidemiologic and virologic characteristics, 2012-2016 Measles surveillance and laboratory performance indicators, 2012-2016 Source: Measles and rubella elimination Annual Status Update report, 2012-2016 Incidence calculated per 1 million population ND = Data not available; NA= Not applicable Source: ASU 2012-2016, MeaNS 2012-2016 and laboratory accreditation results 2012-2016 ND = Data not available; NA= Not applicable A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory Rubella incidence, epidemiologic and virologic characteristics, 2012-2016 Rubella surveillance and laboratory performance indicators, 2012-2016 Source: Measles and rubella elimination Annual Status Update report, 2012-2016 Incidence calculated per 1 million population ND = Data not available; NA= Not applicable Source: ASU 2012-2016, RubeNS 2012-2016 and laboratory accreditation results 2012-2016 ND = Data not available; NA= Not applicable A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory Measles and rubella elimination country profile Hungary ©WHO 2018 Discarded non- measles rate % 1st sub- national unit with ≥ 2 discarded cases % cases with adequate laboratory investiga- tion % origin of infection known # specimen tested for measles % positive for measles Rate of viral detection % WHO and proficient labs 2012 ND ND 100% 100% ND ND ND ND 2013 0.1 ND 100% 100% ND ND ND ND 2014 NA NA 100% NA 2 0% NA ND 2015 0.0 ND 100% NA 71 0% NA 100% 2016 0.0 NA 100% NA 89 0% NA 100% Suspected rubella cases Confirmed measles cases Discarded as non- rubella Rubella incidence Genotypes detected Laboratory Epi- linked Clincally Total 2012 ND 7 0 0 7 ND 6 ND 2013 11 0 0 0 0 11 0 NA 2014 5 0 0 0 0 5 0 NA 2015 3 0 0 0 0 3 0 NA 2016 10 0 0 0 0 10 0 NA Discarded non- rubella rate % 1st sub- national unit with ≥ 2 discarded cases % cases with adequate laboratory investiga- tion % origin of infection known # specimen tested for rubella % positive for rubella Rate of viral detection % WHO and proficient labs 2012 ND ND 100% 29% ND ND ND ND 2013 0.1 ND 100% NA ND ND NA ND 2014 0.1 ND 100% NA 5 0% NA ND 2015 0.0 ND 100% NA 98 0% NA 100% 2016 0.1 ND 100% NA 90 0% NA 100% RVC comments, based on 2016 reporting The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in Hungary in 2016, and confirmed that measles and rubella elimination has been sustained. The RVC commends Hungary for sustaining a very high level of population immunity. It urges the National Verification Committee (NVC) and national health authorities to strengthen measles and rubella surveillance to the level considered ade- quate (with a rate of measles and rubella discarded cases ≥2/100 000) and to improve the way in which surveillance performance is presented in the ASU in order to facilitate better documentation of the elimination status. Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC) No cases reported Source: Measles and rubella elimination Annual Status Update report, 2016 CRS = congenital rubella syndrome Information on CRS, 2016 Surveillance performance indicators and targets a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population b. % cases with adequate laboratory investigation: ≥ 80% c. % origin of infection known: ≥ 80% d. Rate of viral detection: ≥ 80%